Cancer immunotherapy,largely based on programmed cell death-1(PD-1)/PD-ligand 1(PD-L1)immune checkpoint blockade,has achieved remarkable advancements over the past decade in the treatment of human cancers[1,2],includi...Cancer immunotherapy,largely based on programmed cell death-1(PD-1)/PD-ligand 1(PD-L1)immune checkpoint blockade,has achieved remarkable advancements over the past decade in the treatment of human cancers[1,2],including a subset of gastrointestinal malignancies[3].展开更多
基金supported by the National Natural Science Foundation of China(81930065,82173128,and 82003269)the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences(CIFMS)(2019-I2M-5-036)。
文摘Cancer immunotherapy,largely based on programmed cell death-1(PD-1)/PD-ligand 1(PD-L1)immune checkpoint blockade,has achieved remarkable advancements over the past decade in the treatment of human cancers[1,2],including a subset of gastrointestinal malignancies[3].
